magnifying glass
logo for Lumos Pharma

Lumos Pharma

Manufacturing · Texas, United States · 29 Employees

Get Full Access

Who is Lumos Pharma

Lumos Pharma, based in Austin, Texas, is focused on developing novel therapies for patients with unmet medical needs in rare and neglected diseases. Lumos Pharma is a proud awardee of the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program. The TRND program collaborates with biotechnology companies in the development of early stage technologies that show promise for the treatment of rare diseases. The TRND program provides in-kind scientific and financial support for the preclinical program to allow for the commencement of clinical trials in human subjects. Lumos Pharma's lead compound, LUM001, is a novel treatment for the rare disease, Creatine Transporter Deficiency (CTD). CTD is a relatively new and rare disorder, initially described in 2001, and is thought to be the second most common cause of X-linked intellectual disability and developmental delay after Fragile X Syndrome. The inability to transport creatine can lead to intellectual disability, developmental delay,expressive speech deficits, autistic behaviors, and seizures. Many boys are misdiagnosed with autism due to the clinical presentation. LUM001 has been granted orphan status in the US and is in preclinical development in partnership with scientists at the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, through its Therapeutic for Rare and Neglected Diseases program. This NCATS collaboration has helped advance the lead molecule LUM001 as a clinical candidate by generating the data needed to file an investigational new drug application with the Food and Drug Administration. Additionally, Lumos Pharma has partnered with Key Opinion Leaders in the field in conducting a preclinical and clinical development program to evaluate the safety and efficacy of its promising drug candidate for the treatment of CTD.Read More

Headquarters

Headquarters:

4200 Marathon Blvd, Ste 200, Austin, Texas, 78756, United States
Phone Number

Phone Number:

(512) 215-2630
Revenue

Revenue:

<$5 Million
Stock Symbol

Stock Symbol:

LUMO
Lumos Pharma's Social Media
SIC Code 28,87
NAICS Code 541712,3254
Ticker NASDAQ: LUMO
Popular Searches:

Lumos Pharma Inc

Lumos Pharma , Inc.

Lumos Pharma

Lumos Pharma, Inc.

investors.lumos-pharma.com

Top Competitors of Lumos Pharma

Employess
<25
revenue
<$5 Million

1

Employess
<25
revenue
<$5 Million

2

Employess
<25
revenue
<$5 Million

3

Employess
27
revenue
$5 Million

4

Employess
26
revenue
$5 Million

5

Employess
<25
revenue
<$5 Million

6

Lumos Pharma's Org Chart

Rick Hawkins
Rick Hawkins

Chief Executive Officer & Chairman ...

PhonePhoneEmailEmail
Lori Lawley
Lori Lawley

Chief Financial Officer

PhonePhoneEmailEmail
Carl Langren
Carl Langren

Chief Financial Officer

PhonePhoneEmailEmail

PhonePhoneEmailEmail
Illustration of an envelope

Lumos Pharma Company Metrics

Company Insights
Employee Growth Rate
Funding
Funding DateRoundAmountInvestors

Apr 03, 2016

Series B

$34M

Clarus Ventures

Jan 23, 2014

Series A

$13M

Sante Ventures

See More

$47M

Total Funding Amount

$34M

Most Recent Funding Amount

2

Number of Funding Rounds

Revenue
QuarterRevenue

'21 - Q1

5794000

'21 - Q2

5794000

Lumos Pharma's Tech Stack

Lumos Pharma News & Media

Lumos Pharma to Participate in Upcoming Investor Conferences

AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferences:

Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call Transcript

Lumos Pharma, Inc. (NASDAQ:NASDAQ:LUMO) Q1 2022 Earnings Conference Call May 10, 2022, 16:30 ET Company Participants Lisa Miller - Senior Director, IR Richard Hawkins - CEO & Chairman...

Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDA The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDA
Subscribe to "Lumos Pharma" News

Frequently Asked Questions regarding Lumos Pharma

Where are Lumos Pharma’s headquarters?

Lumos Pharma’s headquarters are in 4200 Marathon Blvd, Ste 200, Austin, Texas, 78756, United States

What is Lumos Pharma’s phone number?

Lumos Pharma’s phone number is (512) 215-2630

What is Lumos Pharma’s stock symbol?

Lumos Pharma’s stock symbol is LUMO

What is Lumos Pharma’s official website?

Lumos Pharma’s official website is www.lumos-pharma.com

What is Lumos Pharma’s Revenue?

Lumos Pharma’s revenue is <$5 Million

What is Lumos Pharma’s SIC code?

Lumos Pharma’s SIC: 28,87

What is Lumos Pharma’s NAICS code?

Lumos Pharma’s NAICS: 541712,3254

How many employees are working in Lumos Pharma?

Lumos Pharma has 29 employees

What is Lumos Pharma’s industry?

Lumos Pharma is in the industry of: Manufacturing, Pharmaceuticals, Business Services

Who are Lumos Pharma’s main competitors?

Lumos Pharma's main competitors are: Precision Biologics, Patrys, OxThera, AngioChem

What is Lumos Pharma's tech stack?

The technologies that are used by Lumos Pharma are: Cloudflare CDN, Slack, PHP, nginx

Who is Lumos Pharma's CEO?

Lumos Pharma's CEO is Rick Hawkins

Who is Lumos Pharma's CFO?

Lumos Pharma's CFO is Carl Langren

See more information about Lumos Pharma
4.4/5 on G2 Crowd